Federal prosecutors last week leveled conspiracy and fraud charges against 2 former executives of Acclarent for an alleged off-label marketing scheme for the Relieva Stratus microflow spacer.
NxThera said it closed a $20 million Series C round that topped its initial $18 million target.
Maple Grove, Minn.-based NxThera won CE Mark approval in the European Union last August for its Rezūm prostate device, which uses steam to reduce the size of the prostate to relieve urinary symptoms from benign prostate hyperplasia.
NxThera said it closed on a Series C round worth $18.2 million and won CE Mark approval for its Rezum treatment for benign prostatic hyperplasia.
Maple Grove, Minn.-based NxThera’s device uses steam to reduce the size of the prostate to relieve urinary symptoms from BPH, according to NxThera’s website.
NxThera reported raising $3.5 million in an April 4 regulatory filing:
Raise: $3.5 million
Security: Debt; Options/Warrants
Sales Commission: $0
Entegrion landed a $43.7 million dollar contract with the Dept. of Defense for its Resusix proprietary dehydrated pathogen-inactivated human plasma.
Resusix holds promise as a substitute for fresh frozen plasma in certain situations. The Defense Dept. contract will fund Resusix’s development through Phase III clinical trials and biological license application.
Startup Thermalin Diabetes LLC closed a $2.85 million Series A investment round.
The Cleveland-based synthetic insulin developer plans to use the funding to step up production of its insulin analogs — new proteins engineered to act like insulin in the body — and continue preclinical testing.
Word is out about the identity of the corporate partner NxThera CEO Robert Paulson mentioned last week: American Medical Systems Inc. (NSDQ:AMMD).
AMS specializes in medical devices related to pelvic health. NxThera is developing a thermal vapor prostate treatment that involves the same area of the body where American Medical Systems’ expertise lies.